Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

EF Hutton Maintains Buy on Hoth Therapeutics, Lowers Price Target to $33

EF Hutton analyst Constantine Davides maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and lowers the price target from $45 to $33.
byBenzinga Newsdesk
December 30, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

EF Hutton analyst Constantine Davides maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and lowers the price target from $45 to $33.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0